All Stories

  1. Microglia in Parkinson’s Disease
  2. Host oligodendrogliopathy and ɑ-synuclein strains dictate disease severity in multiple system atrophy
  3. The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy
  4. Spreading of Aggregated α-Synuclein in Sagittal Organotypic Mouse Brain Slices
  5. Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy
  6. The Concept of α-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders
  7. Toll-like receptor 4 deficiency facilitates α-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease
  8. Is Multiple System Atrophy a Prion-like Disorder?
  9. Current experimental disease-modifying therapeutics for multiple system atrophy
  10. Neuropathology of multiple system atrophy: Kurt Jellinger`s legacy
  11. ATH434 Reduces α‐Synuclein‐Related Neurodegeneration in a Murine Model of Multiple System Atrophy
  12. Phenotypic Characterization and Brain Structure Analysis of Calcium Channel Subunit α2δ-2 Mutant (Ducky) and α2δ Double Knockout Mice
  13. Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease
  14. Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
  15. From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein
  16. Signs of early cellular dysfunction in multiple system atrophy
  17. Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies
  18. Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in α‐Synucleinopathies
  19. Shock waves promote spinal cord repair via TLR3
  20. Assessment of the Retina of Plp-α-Syn Mice as a Model for Studying Synuclein-Dependent Diseases
  21. Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease
  22. MSA: From basic mechanisms to experimental therapeutics
  23. Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy
  24. High-salt diet does not boost neuroinflammation and neurodegeneration in a model of α-synucleinopathy
  25. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy
  26. Neuroinflammation and Glial Phenotypic Changes in Alpha-Synucleinopathies
  27. Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges
  28. L-dopa response pattern in a rat model of mild striatonigral degeneration
  29. Increased anxiety-like behavior following circuit-specific catecholamine denervation in mice
  30. Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy
  31. Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
  32. Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived α-synuclein in oligodendroglia: implications for MSA pathogenesis
  33. Translational therapies for multiple system atrophy: Bottlenecks and future directions
  34. The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint
  35. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies
  36. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting
  37. Multiple system atrophy: experimental models and reality
  38. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy
  39. Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease
  40. Very late-onset pure autonomic failure
  41. Distinct Parameters in the EEG of the PLP α-SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity
  42. Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy
  43. Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy
  44. Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications
  45. Microglia activation as a therapeutic target in multiple system atrophy: the timing, the good and the bad
  46. Preface
  47. Review: Multiple system atrophy: emerging targets for interventional therapies
  48. Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies
  49. Glia and alpha-synuclein in neurodegeneration: A complex interaction
  50. Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity
  51. Shock Wave Treatment Protects From Neuronal Degeneration via a Toll‐Like Receptor 3 Dependent Mechanism: Implications of a First‐Ever Causal Treatment for Ischemic Spinal Cord Injury
  52. Involvement of Peripheral Nerves in the Transgenic PLP-α-Syn Model of Multiple System Atrophy: Extending the Phenotype
  53. Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder
  54. Alpha-synuclein immunoreactivity patterns in the enteric nervous system
  55. Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications
  56. Animal models of multiple system atrophy
  57. Multiple System Atrophy: Genetic or Epigenetic?
  58. Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies
  59. Towards translational therapies for multiple system atrophy
  60. CaV1.2 Calcium Channel Expression in Reactive Astrocytes is associated with the Formation of Amyloid-β Plaques in an Alzheimer's Disease Mouse Model
  61. Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: Experimental evidence
  62. Intact Olfaction in a Mouse Model of Multiple System Atrophy
  63. Bladder dysfunction in a transgenic mouse model of multiple system atrophy
  64. Models of Multiple System Atrophy
  65. Cell Fate Analysis of Embryonic Ventral Mesencephalic Grafts in the 6-OHDA Model of Parkinson's Disease
  66. Toll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astroglia
  67. The Role of Glia in Alpha-Synucleinopathies
  68. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy
  69. Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model
  70. Toll-Like Receptor 4 Promotes α-Synuclein Clearance and Survival of Nigral Dopaminergic Neurons
  71. Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection
  72. Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
  73. Nogo-B is associated with cytoskeletal structures in human monocyte-derived macrophages
  74. Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy
  75. Targeted overexpression of human α-synuclein in oligodendroglia induces lesions linked to MSA -like progressive autonomic failure
  76. Kappa opioid receptor activation blocks progressive neurodegeneration after kainic acid injection
  77. Multiple system atrophy: an update
  78. Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy
  79. Striatal transplantation for multiple system atrophy — Are grafts affected by α-synucleinopathy?
  80. Recent developments in multiple system atrophy
  81. Striatal transplantation in a rodent model of multiple system atrophy: Effects on L-Dopa response
  82. Multiple system atrophy: A primary oligodendrogliopathy
  83. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy
  84. Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme
  85. Microglial activation mediates neurodegeneration related to oligodendroglial α-synucleinopathy: Implications for multiple system atrophy
  86. High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence
  87. Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy
  88. Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy
  89. Animal models of multiple system atrophy
  90. Oxidative Stress in Transgenic Mice with Oligodendroglial α-Synuclein Overexpression Replicates the Characteristic Neuropathology of Multiple System Atrophy
  91. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats
  92. In vitro models of multiple system atrophy
  93. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy)
  94. Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy)
  95. Effects of pulsatile l-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
  96. Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment
  97. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration
  98. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy)
  99. Tumor necrosis factor-?-induced cell death in U373 cells overexpressing ?-synuclein
  100. Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys
  101. Freezing of gait in postmortem‐confirmed atypical parkinsonism
  102. Ultrastructure of α-synuclein-positive aggregations in U373 astrocytoma and rat primary glial cells
  103. Overstimulation of the α1B-adrenergic receptor causes a “seizure plus” syndrome
  104. Glial cell death induced by overexpression of ?-synuclein
  105. Multiple System Atrophy
  106. Failure of Neuroprotection by Embryonic Striatal Grafts in a Double Lesion Rat Model of Striatonigral Degeneration (Multiple System Atrophy)
  107. γ-Aminobutyric acid-immunoreactive neurons in the amygdala of the rat – sex differences and effect of early postnatal castration
  108. Sex and age differences of neurons expressing gaba‐immunoreactivity in the rat bed nucleus of the stria terminalis